Sharon Barbari
CIK 1240499 · EVP, Finance & CFO · last filed 2025-12-15
Sharon Barbari is an EVP, Finance & CFO who has filed 48 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for VYNE, was dated Dec 15, 2025. Current disclosed insider exposure totals $2.4M across reported positions. 17 SEC filings were submitted jointly with Oculus Innovative Sciences, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CYTK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc. (VYNE) Delisted | Director | — | $28.56 | — | $0 | 6 | 2025-12-15 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | Director | 974 | $1.51 | $1.5K | $0 | 4 | 2023-06-09 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | 75,000 | — | — | $0 | 4 | 2020-08-21 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Director | — | — | — | $0 | 1 | 2019-05-20 |
| Sonoma Pharmaceuticals, Inc. (SNOAW) Delisted | Director | 43,417 | — | — | $0 | 6 | 2018-03-02 |
| CYTK | EVP, Finance & CFO | 40,323 | $60.73 | $2.45M | $0 | 15 | 2017-03-02 |
| Sonoma Pharmaceuticals, Inc. (OCLSW) Delisted | Director | 6,244 | — | — | $0 | 1 | 2016-11-30 |
| Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Director | 5,209 | — | — | $0 | 4 | 2016-08-30 |
| Sonoma Pharmaceuticals, Inc. (OCLS.W) Delisted | Director | 4,356 | — | — | $0 | 5 | 2016-03-02 |
Recent Filings
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-15 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-12-13 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-08-26 | — | Disp (D) | −973 | -$1.5K | |
| 2024-01-03 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-15 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | +935 | $0 | EDGAR |
| 2022-08-12 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-10 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | +670 | $0 | EDGAR |
| 2021-07-20 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-10 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | +24,510 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.